Atea Pharmaceuticals, Inc. Common Stock (AVIR)
Atea Pharmaceuticals, Inc. (AVIR) is a biotechnology company focused on developing innovative antiviral therapies for infectious diseases. The company leverages its proprietary research platform to discover and advance new treatments for viral illnesses, with an emphasis on respiratory viruses such as COVID-19. Atea collaborates with partners and clinical organizations to accelerate the development of its pipeline candidates.
Company News
Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss second quarter 2025 financial results and provide a business update, focusing on their HCV treatment development program.
Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report its third-quarter 2024 results. The company is expected to see strong growth in its business segments, particularly in the Hip and Knees businesses. However, the Zacks Consensus Estimate for earnings has moved slightly lower in the past 30 days.
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
AVIR earnings call for the period ending June 30, 2022.
Shares of Atea Pharmaceuticals Inc. were trading over 18% higher in the after-hours market Monday, following the company's release of fourth-quarter financial results and news of upcoming drug trials.